Trial Profile
A Randomised, Single-blind, Placebo-controlled, Dose-escalation Study to Assess the Safety and Tolerability of Single and Repeat, Inhaled Doses of PC786 in Healthy Subjects Combined With a Randomised, Single-blind, Placebo-controlled, Parallel Group to Assess the Safety and Tolerability of a Single Dose of Inhaled PC786 in Subjects With Mild Asthma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Nov 2018
Price :
$35
*
At a glance
- Drugs PC-786 (Primary)
- Indications Asthma; Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Pulmocide
- 07 Oct 2018 Results presented at the IDWeek 2018
- 28 Sep 2018 According to a Pulmocide media release, data from this study will be presented at the ID week ( Oct 2018).
- 20 Dec 2017 Status changed from active, no longer recruiting to completed.